Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Methodology breakdown not tracked for 3649.T yet — our own seven-methodology screen needs filed financials we do not have for this symbol. The verdict above is our compliance provider's, unchanged.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Not tracked for 3649.T yet — our own seven-methodology screen runs off filed financials, and we do not have them for this symbol. The verdict above is our compliance provider's, unchanged and not affected by this.
Verdict history for 3649.T. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
Tracked since 2026-09-07.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 58.70 | NEUTRAL |
| Stochastic %K (14) | 81.65 | SELL |
| CCI (20) | 118.60 | SELL |
| Williams %R (14) | -18.35 | SELL |
| MACD (12,26,9) | 7.20 | BUY |
| ROC (10) | 5.29 | BUY |
| Momentum (10) | 45.00 | BUY |
| EMA (10) | 879.26 | BUY |
| SMA (10) | 868.00 | BUY |
| EMA (20) | 867.16 | BUY |
| SMA (20) | 860.45 | BUY |
| EMA (30) | 861.27 | BUY |
| SMA (30) | 861.30 | BUY |
| EMA (50) | 852.09 | BUY |
| SMA (50) | 859.24 | BUY |
| EMA (100) | 839.83 | BUY |
| SMA (100) | 818.64 | BUY |
| EMA (200) | 843.52 | BUY |
| SMA (200) | 843.29 | BUY |
Healthcare · Health Information Services
FINDEX Inc. offers medical devices in Japan. It operates through Medical Business, Public Business, and Healthtech Business segments. The company provides Claio image filing system, C-Scan paper and digital document management system, DocuMaker document creation system, PDI+MoveBy referral information management system, C-Note medical record writing system, MapleNote perinatal system, REMORA electronic medical record, ID-Cam/Claio-Cam digital camera solution, UniversalSearcher medical big data search system, FAXde regional collaboration FAX referral management system, LIS endoscope system endoscopy department system, LIS ultrasound system ultrasound department system, ProRad RS radiology reporting system, gateway system, RemoTalkCloud, remote sharing app for medical information, C-Nys / C-Nys ME Nystagmus analysis support system, Cloud backup service security service, PiCls Medical Avenue for patient information app, PiCls On-examination online medical support system, PiCls AAdE-report electronic tracing report service, PiCls booking assistant first appointment online reservation service, PiCls connect medical institution collaboration service, WebeLi, and CocktailAI ,a generative AI for medical text generation; and DigiWorker, an RPA tool for healthcare. It also offers REMORA+Claio, an ophthalmology solution; G-QuICC DB Program, a glaucoma protocol; ENT package; DocuMaker Cloud, a medical certificate and other document creation service; REMORA Cloud, a cloud-based electronic medical record; C-Note + Claio, an ophthalmology solution; ClaioDashboard integrated viewing system; DocuMaker office, a document management system for administrative department; DocuMakerShelf, an electronic bookkeeping solution; and GAP-screener, line-of-sight analysis type perimeter for medical examination facilities. The company was formerly known as PSC Inc. and changed its name to FINDEX Inc. in November 2014. FINDEX Inc. was incorporated in 1985 and is headquartered in Chiyoda, Japan.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2025-12-31, figures in JPY.
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.